Caution required for biosimilars

While they present a cost-saving opportunity, safety data on biosimilars is still limited, warns IBD specialist There is an absence of data on adverse reactions or potential development of anti-drug antibodies caused by the use of biosimilars, warns Dr Greg Moore, Head of IBD at Monash Medical Centre in Melbourne and a Senior Lecturer in

This content is restricted. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous World news wrapup: 6 October 2016
Next Forum: why havent I reached the safety net yet?